ArticleBMC gastroenterology2026

Cost-effectiveness analysis of durvalumab combined with tremelimumab versus sorafenib as first-line treatment for unresectable Hepatocellular carcinoma in China: a dual-model approach utilizing partitioned survival and markov models.

Ruixuan Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.